Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
作者信息
Bajwa Amneet, Huang Ying, Li Rui, Denlinger Nathan, Brammer Jonathan, Penza Sam, Saad Ayman, Jaglowski Samantha, Kittai Adam S
机构信息
Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Division of Hematology, The Ohio State University, Columbus, OH, USA.
出版信息
Leuk Lymphoma. 2022 Jun;63(6):1492-1495. doi: 10.1080/10428194.2022.2032039. Epub 2022 Feb 3.
Abstract
摘要
相似文献
1
Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.嵌合抗原受体T细胞（CAR-T）疗法治疗弥漫性大B细胞淋巴瘤后早期成像的预后价值
Leuk Lymphoma. 2022 Jun;63(6):1492-1495. doi: 10.1080/10428194.2022.2032039. Epub 2022 Feb 3.
2
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.早期正电子发射断层扫描在接受抗CD19嵌合抗原受体T细胞疗法治疗的大B细胞淋巴瘤患者中的预后价值
Haematologica. 2023 Dec 1;108(12):3433-3437. doi: 10.3324/haematol.2022.282345.
3
CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.嵌合抗原受体T细胞（CAR-T）疗法作为大B细胞淋巴瘤二线治疗优于标准治疗：一项系统评价和荟萃分析。
Br J Haematol. 2023 Jan;200(1):e4-e5. doi: 10.1111/bjh.18506. Epub 2022 Oct 25.
4
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.CD19 和 CD20 靶向嵌合抗原受体 T 细胞联合给药治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 II 期临床试验。
Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1.
5
CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report.CD19 CAR-T 细胞治疗引起的免疫治疗相关性间质性肺炎：一例报告。
Front Immunol. 2022 Jan 27;13:778192. doi: 10.3389/fimmu.2022.778192. eCollection 2022.
6
CAR T cell therapy for B-cell lymphomas.用于B细胞淋巴瘤的嵌合抗原受体T细胞疗法。
Best Pract Res Clin Haematol. 2018 Jun;31(2):135-146. doi: 10.1016/j.beha.2018.04.001. Epub 2018 Apr 11.
7
A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.弥漫性大B细胞淋巴瘤的第二轮抗CD19嵌合抗原受体T细胞疗法：持续治疗何时能取得成效。
Leuk Lymphoma. 2024 Jun;65(6):868-871. doi: 10.1080/10428194.2024.2325188. Epub 2024 Mar 5.
8
Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.在难治性弥漫性大B细胞淋巴瘤中，抗CD19嵌合抗原受体T细胞疗法后，PD-1抑制导致肿瘤快速消退。
Bone Marrow Transplant. 2020 Jun;55(6):1184-1187. doi: 10.1038/s41409-019-0657-3. Epub 2019 Aug 30.
9
Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.嵌合抗原受体T细胞疗法治疗HIV相关弥漫性大B细胞淋巴瘤：病例报告及管理建议
Bone Marrow Transplant. 2021 Mar;56(3):679-682. doi: 10.1038/s41409-020-01018-7. Epub 2020 Aug 6.
10
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.T细胞/组织细胞丰富的大B细胞淋巴瘤对CD19导向的嵌合抗原受体T细胞疗法的原发性耐药
Blood. 2021 Jun 17;137(24):3454-3459. doi: 10.1182/blood.2020009148.
本文引用的文献
1
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.替沙格赛定用于儿童急性淋巴细胞白血病和非霍奇金淋巴瘤的真实世界证据。
Blood Adv. 2020 Nov 10;4(21):5414-5424. doi: 10.1182/bloodadvances.2020003092.
2
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
3
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.阿基仑赛用于复发或难治性大 B 细胞淋巴瘤的标准治疗：来自美国淋巴瘤嵌合抗原受体 T 细胞治疗联盟的结果。
J Clin Oncol. 2020 Sep 20;38(27):3119-3128. doi: 10.1200/JCO.19.02104. Epub 2020 May 13.
4
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies.用于B细胞恶性肿瘤的多靶点嵌合抗原受体T细胞疗法
Front Oncol. 2019 Mar 12;9:146. doi: 10.3389/fonc.2019.00146. eCollection 2019.
5
Mechanisms of resistance to CAR T cell therapy.CAR T 细胞治疗耐药的机制。
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. doi: 10.1038/s41571-019-0184-6.
6
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
7
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
8
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.来那度胺维持治疗对比安慰剂用于一线利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗的老年弥漫性大 B 细胞淋巴瘤患者。
J Clin Oncol. 2017 Aug 1;35(22):2473-2481. doi: 10.1200/JCO.2017.72.6984. Epub 2017 Apr 20.
9
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.霍奇金淋巴瘤和非霍奇金淋巴瘤初始评估、分期及反应评估的建议：卢加诺分类
J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
Zotero 插件